Tigertriever in the treatment of acute ischemic stroke with underlying intracranial atherosclerotic disease

• Published in: Journal of neurointerventional surgery Vol. 16; no. 11; p. 1083
• Main Authors: Ojeda, Diego J, Ghannam, Malik, Sanchez, Sebastian, Almajali, Mohammad, Koul, Prateeka, Saver, Jeffrey L, Gupta, Rishi, Ortega-Gutierrez, Santiago, Liebeskind, David S, Samaniego, Edgar A
• Format: Journal Article
• Language: English
• Published: BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 14.10.2024; BMJ Publishing Group LTD
• Subjects: Aged; Aged, 80 and over; Atherosclerosis; Endovascular Procedures - methods; Female; Hemorrhage; Humans; Intracranial Arteriosclerosis - diagnostic imaging; Intracranial Arteriosclerosis - surgery; Ischemia; Ischemic stroke; Ischemic Stroke - diagnostic imaging; Ischemic Stroke - surgery; Ischemic Stroke - therapy; Male; Medical imaging; Middle Aged; Patients; Performance evaluation; Stroke; Thrombectomy; Thrombectomy - methods; Treatment Outcome; Variables; Veins & arteries; United States > US; Stroke; Thrombectomy; Atherosclerosis
• ISSN: 1759-8478; 1759-8486
• DOI: 10.1136/jnis-2023-020796

BackgroundThe Tigertriever device offers a unique feature that enables gradual control of the radial expansion. We sought to evaluate the safety and efficacy of the Tigertriever device in patients with large vessel occlusion (LVO) and underlying intracranial atherosclerotic disease (ICAD). The patients were part of the TIGER trial.MethodsThe presence of underlying ICAD was determined by a core imaging laboratory using CT angiography and digital subtraction angiography. The primary outcomes included successful reperfusion, puncture to reperfusion time, and complications associated with the use of the Tigertriever device. Patients underwent mechanical thrombectomy with the Tigertriever device for up to three passes, and alternative devices were employed for subsequent passes.ResultsA total of 160 patients were enrolled in the TIGER trial, and 32 patients had ICAD. Among the patients with ICAD, 78% achieved successful reperfusion within three passes of the Tigertriever device, without requiring rescue therapy. Additionally, a first pass effect was observed in 46.8%. The median time from puncture to reperfusion was 22 minutes. There were no device-related complications. The National Institutes of Health Stroke Scale (NIHSS) score at 24 hours was significantly reduced, from an average of 17 at baseline to 8. At the 3 month follow-up, 50% of patients achieved a modified Rankin Scale score of ≤2.ConclusionEndovascular therapy (EVT) with the Tigertriever device for LVO in patients with underlying ICAD is effective and safe. When compared with historical data from other devices employed in similar cases, we observed a high rate of successful reperfusion, along with a shorter puncture to reperfusion time.